**Home-Based Intervention to Test and Start (HITS): A community-randomized controlled trial to increase HIV testing uptake among men in rural South Africa**

Frank C Tanser1,2,3,4\*§, Hae-Young Kim1,5,6\*, Thulile Mathenjwa1, Maryam Shahmanesh1,7, Janet Seeley1,8, Phillippa Matthews1, Sally Wyke9, Nuala McGrath1,10, Oluwafemi Adeagbo1,11,12, Benn Sartorius3,8, Handurugamage Manisha Yapa1,13, Thembelihle Zuma1, Anya Zeitlin7, Ann Blandford14, Adrian Dobra15, Till Bärnighausen1,16

1 Africa Health Research Institute, KwaZulu-Natal, South Africa

2 Lincoln International Institute for Rural Health, University of Lincoln, Lincoln, United Kingdom

3 School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa

4 Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa

5 Department of Population Health, New York University School of Medicine, New York, USA

6 KwaZulu-Natal Innovation and Sequencing Platform, KwaZulu-Natal, South Africa

7 Institute for Global Health, University College London, London, United Kingdom

8 London School of Hygiene and Tropical Medicine, London, United Kingdom

9 University of Glasgow, Glasgow, United Kingdom

10 University of Southampton, Southampton, United Kingdom

11 Department of Sociology, University of Johannesburg, Johannesburg, South Africa

12 Department of Health Promotion, Education and Behaviour, University of South Carolina, South Carolina, USA

13 The Kirby Institute, University of New South Wales, Sydney, Australia

14 University College London Interaction Centre, University College London, London, United Kingdom

15 University of Washington, Washington, USA

16 Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany

§ Corresponding author: Frank Tanser

Africa Health Research Institute

719 Umbilo Road, KwaZulu-Natal, South Africa

FTanser@ahri.org; FTanser@lincoln.ac.uk

\*These authors have contributed equally to the work.

E-mail addresses of authors:

FT: FTanser@lincoln.ac.uk

H-YK: hae-young.kim@nyulangone.org

TM: Thulile.Mathenjwa@ahri.org

MS: m.shahmanesh@ucl.ac.uk

JS: janet.seeley@lshtm.ac.uk

PM: Philippa.Matthews@ahri.org

SW: sally.wyke@glasgow.ac.uk

NM: n.mcgrath@soton.ac.uk

OA: Oluwafemi.Adeagbo@ahri.org

BS: Benn.Sartorius1@lshtm.ac.uk

HMY: myapa@kirby.unsw.edu.au

TZ: Thembelihle.Zuma@ahri.org

AZ: anya.zeitlin.16@ucl.ac.uk

AB: a.blandford@ucl.ac.uk

AD: adobra@uw.edu

TB: till.baernighausen@uni-heidelberg.de

Keywords: Home-based HIV testing, men, financial incentives, counselling, mHealth, randomized controlled trial, South Africa

Word count:

Abstract: 379/350

Main text: 3838/3500

**Abstract**

**Introduction:** The uptake of HIV testing and linkage to care remain low among men, contributing to high HIV incidence in women in South Africa. We conducted the “Home-Based Intervention to Test and Start” (HITS) in a 2x2 factorial cluster randomized controlled trial in rural South Africa to increase HIV testing enhancing both intrinsic and extrinsic motivations.

**Methods:** Between February and December 2018, we randomly assigned 45 communities (clusters) (n=13,838 residents) in the uMkhanyakude district of KwaZulu-Natal to one of the four arms: (i) financial incentives for home-based HIV testing and linkage to care (R50 [$3] food voucher each); (ii) male-targeted HIV-specific decision support application, called EPIC-HIV; (iii) both financial incentives and male-targeted HIV-specific decision support application; and (iv) standard of care (SoC). EPIC-HIV was developed to encourage and serve as an intrinsic motivator for HIV testing and linkage to care, and individually offered to men via a tablet device. Financial incentives were offered to both men and women. Here we report the effect of the interventions on uptake of home-based HIV testing among men. Intention-to-treat (ITT) analysis was performed using modified Poisson regression with adjustment for clustering of standard errors at the cluster levels.

**Results:** Among all 13,838 men ≥15 years living in the 45 communities, the overall population coverage during a single round of home-based HIV testing was 20.7%. The uptake of HIV testing was 27.5% (683/2481) in the financial incentives arm, 17.1% (433/2534) in the EPIC-HIV arm, 26.8% (568/2120) in the arm receiving both interventions, and 17.8% in the SoC arm. The probability of HIV testing increased substantially by 55% in the financial incentives arm (risk ratio (RR)=1.55, 95% CI: 1.31-1.82, p<0.001) and 51% in the arm receiving both interventions (RR=1.51, 95% CI: 1.21-1.87 p<0.001), compared to the SoC arm. It did not significantly differ in the EPIC-HIV arm (RR=0.96, 95% CI: 0.76-1.20, p=0.70).

**Conclusions:** The provision of a small financial incentive acted as powerful extrinsic motivator for home-based HIV testing among men in rural South Africa. By contrast, the counselling and testing application did not increase the uptake of home-based testing at the time of testing offer.

Clinical Trial Number: ClinicalTrials.gov # NCT03757104

**Introduction**

Despite the successes and implementation of population-wide HIV prevention and treatment programs,1,2 female adolescents and young women have consistently faced a high risk of HIV infection while HIV incidence steadily decreased among males, widening the gender gap in many generalized HIV epidemic settings.3–6 Men are less likely to test for HIV and link to care once tested positive, leading to worse long-term health outcomes such as unsuppressed viral load and higher HIV-related mortality among males and reciprocally high HIV incidence among females.1,7 In rural South Africa, once antiretroviral therapy (ART) coverage among males surpassed 35% in 2014, population-level HIV incidence among females significantly declined.8

Recent community-based trials of universal testing and treatment (UTT) including our Test-as-Prevention (TasP) trial (ANRS 12249) in rural South Africa achieved no significant or somewhat modest reduction in HIV incidence at the population level.9–12 One of the key challenges consistent across these trials was missing men and young people - who were disproportionally reached and consent for HIV testing, and less likely to link to and remain in care.12 The trials highlighted that it is not sufficient to merely provide home-based HIV counselling and testing and universal treatment, but effective strategies must be accompanied to increase the uptake of HIV counselling and testing (HCT) and linkage to care at clinics.

Financial incentives have been used to promote various healthy behaviours such as medication adherence,13 reduction of substance misuse,14 or use of preventive services including voluntary medical male circumcision,15–17 Recently, several clinical trials showed promising results that financial incentives could increase the uptake of HIV testing as well as linkage to care and viral load suppression but the efficacy has been varying.18–26 While financial incentives may serve as once-off extrinsic motivation, providing information specific to individuals’ needs can improve intrinsic motivation and empower individuals to make an informed decision to take HCT.27,28

To our knowledge, no study has explicitly quantified the effect of extrinsic vs. intrinsic motivators on the uptake of HIV testing. We conducted a factorial cluster randomized clinical trial - Home-based Intervention to Test and Start (HITS)- in rural KwaZulu-Natal. This trial was built upon the Africa Health Research Institute (AHRI)’s ongoing population-based HIV testing platform. Since 2017, AHRI started offering home-based rapid HIV testing to all eligible individuals during annual HIV surveys. The uptake of home-based rapid HIV testing in 2017 was 26.4% in the overall population and 20.0% among men.29 The overall aim of the trial is to establish whether the provision of small once-off financial incentives and a male-targeted HIV-specific decision support application increases uptake of HIV testing and linkage to HIV care, thus ultimately reducing population-level HIV incidence in (particularly young) women. Here we report the uptake of home-based HIV testing among men, the first registered primary endpoint of the HITS trial.

**Methods**

**Setting**

The trial was nested within the population-based HIV testing platform in uMkhanyakude district of northern KwaZulu Natal.30 HIV prevalence in the study area was estimated as 36.6% in 2016.31 Since 2003, AHRI has conducted ongoing population-based demographic surveillance and individual HIV testing among members of all households residing in the surveillance area. The demographic surveillance is completed with the key informant, which is often the household head or the most senior household member and collects information on demographics of household members including composition, migration events, mortality and marital status. The HIV surveillance is annually conducted among all residents aged ≥15 years and collects data on sexual behavior and general health and dried blood spots (DBS) samples for anonymized HIV testing after obtaining informed consent.30,32 No reimbursement is offered for participation in the HIV surveillance. From 2017, rapid HIV testing has been offered as part of the HIV surveillance during household visits. The surveillance covers 438 km2 geographic area over approximately 90,000 individuals and 60 000 residents at any given time. Through an agreement with the South African Department of Health, the AHRI population-based programme is also linked with the clinical records of patients enrolled in the local public HIV Treatment and Care Programme at the Hlabisa district hospital and 17 primary health care clinics in the Hlabisa health sub-district using the Tier.Net electronic record system since 2004.33 For the patients who out-migrate or link to care outside the 17 clinics, their clinical records could not be captured.

**Trial Design**

This large-scale trial was a 2x2 factorial design delivered to a population of 37,028 residents aged ≥15 years in the four strata with the two interventions, financial micro-incentives and male-targeted HIV-specific decision support, called EPIC-HIV (Empowering People through Informed Choices for HIV), in 45 clusters (“week blocks”) using the AHRI’s ongoing population-based annual HIV testing platform (Figure 1).34 A week block is an area where fieldworkers visit homesteads and complete annual surveys in each week; this was developed using a GPS based methodology to provide equivalent workload to cover the entire surveillance area annually.35 Over the entire study duration, 8 communities received only the financial micro-incentives (i.e. financial incentives only arm), 8 communities received only EPIC-HIV (i.e. EPIC-HIV only arm), 8 communities received both interventions (i.e. financial incentives plus EPIC-HIV arm or combined arm), and 21 communities received standard of care (SoC). Both males and females were eligible to receive the financial incentives but only males were eligible to receive EPIC-HIV. Implementation and acceptance of the HITS intervention were evaluated using process evaluation through post-intervention satisfaction surveys as well as focus group and in-depth interviews among study participants, fieldworkers, and health professionals. The trial was registered at the National Institute of Health (ClinicalTrials.gov # NCT03757104), and the full trial protocol was published elsewhere.34

**Home-based HIV counselling & testing and facilitated linkage to care**

As part of the individual HIV surveillance, a rapid point-of-care HIV test is performed by field workers trained in HCT in accordance with the South African national guidelines. Participants found to be HIV-positive are encouraged to link to care within 7-10 days of the HIV test date, receive a referral slip for an appointment to receive HIV care at their choice of the primary health clinics, and can opt in for facilitated linkage. Individuals who consent for facilitated linkage and have not linked to care within two weeks of the HIV test date receive a single Short Message Service (SMS) message as a reminder. If individuals do not link to care within further two weeks, a trained nurse contacts them by telephone to discuss any concerns and encourage them to link to care. Individuals who were not available at the initial attempt of contact to complete the HIV surveillance are revisited two more times in the same week during normal working hours and then transferred to a tracking team who then attempts to contact participants and make a home visit for three more times in the evenings or weekends before being considered as missing.

**Interventions**

The interventions were delivered in a two-stage scheme for HIV testing and linkage to care. For the financial incentives, participants were first informed and offered a R50 (US ~$3) food voucher for a local supermarket conditional on their participation in rapid HIV testing. Second, participants tested HIV-positive were offered another R50 food voucher if they visited any of the 17 primary health clinics to seek HIV treatment within 6 weeks of the positive HIV test date.

The male-targeted HIV-specific decision support application was implemented and offered via a tablet and available in two versions (EPIC-HIV 1 and EPIC-HIV 2). The content and design of EPIC-HIV were informed by human behaviour change theory and self-determination theory.36 The application development is described in details elsewhere.34 EPIC-HIV 1 was delivered to men prior to the HIV test offer to support their decision whether to take a rapid HIV test or not. The app was designed to be administered in 5-10 min. Participants were able to privately self-navigate the application using a provided earphone and listen to the story of a chosen character. If participants did not link to HIV care within a month of a positive HIV test, a study tracker re-visited and offered them another counselling application (EPIC-HIV 2), which is designed to address barriers to seek HIV treatment and encourage them to link to HIV care.

**Participants**

Individuals were eligible if they were aged ≥15 years and residents of the households within the study area in the 45 clusters, agree to participate in the annual HIV surveillance, and willing to give written informed consent for trial participation. At randomization, we estimated that of approximately 37,000 eligible participants in the 45 clusters, a total of 4,667 individuals would receive HITS interventions in the 24 intervention clusters and 4,900 individuals the standard-of-care in the 21 clusters, considering the expected contact rates and participation rates in the annual population-based HIV testing.34 Written informed consent was sought for trial participation from all eligible individuals ≥18 years, whilst parental/guardian consent with child assent sought for eligible individuals aged 15-17 years.

Individuals were excluded from participation in the study if they have refused to participate in the annual population-based HIV testing or report to be already on ART. Individuals who self-reported as HIV-positive but not on ART were eligible to participate.

**Outcomes**

We report the uptake of home-based HIV testing among men, the first registered primary endpoint of the HITS trial. Uptake was defined as acceptance and completion of home-based HIV testing (with the standard pre- and post-test HIV counselling).

**Randomisation and blinding**

Randomisation was conducted to ensure balance across the arms using stratified sampling at the community-level based on the HIV incidence among young females aged 15-30 years. The 45-week blocks (i.e. community clusters) were divided into four strata according to their HIV incidence rates such that stratum 1 comprised community clusters with the lowest incidence rate, while stratum 4 comprised community clusters with the highest incidence rate. Each of the intervention arms consisted of two community clusters from each of the four incidence strata (thus a total of eight community clusters per arm). The SoC arm consisted of five community clusters from each of the incidence stratum 1, 2, and 4, and six community clusters from incidence stratum 3 (thus a total of 21 community clusters). The trial was an open-labelled without blinding neither to investigators nor participants.

**Sample size and power calculation**

The study was powered to achieve a 25% reduction in HIV incidence among females aged 15–30 years in the intervention arms. Using the AHRI’s actual HIV incidence data, we estimated to be able to detect

a 25% reduction in HIV incidence in the financial incentives only arm, 25% reduction in the EPIC-HIV only arm and a 37% reduction in the combined arm after 3-years of follow-up in >80% of power of simulation replicates (p <0.05), accounting for grouping of the clusters in the four arms. Therefore, if we were to introduce the HITS intervention in 2018 and follow young females for at least 3 years post-intervention (i.e. utilize a total of 17 years of incidence from 2004 to 2021), we would expect to be in excess of 90% power to detect such a reduction in incidence among females aged 15-30 years.

**Implementation**

The trial statistician (AD) performed the stratified randomization of communities prior to intervention rollout. Fieldwork teams enrolled and offered interventions to participants when eligible. Individual consent was sought after cluster randomization.

**Statistical methods**

The primary analysis was conducted using the intent-to-treat (ITT) analysis for all men randomized at the community level. We used generalized linear models with Poisson distribution and robust error terms, adjusting for community-level clustering through random effects. We also examined the effect of financial incentives and EPIC-HIV separately in the factorial analysis and interaction effects between the two interventions. We then limited the analysis to those who participated in the population-based annual HIV survey and were offered the interventions. All analyses were conducted in STATA 15.1 (StataCorp) and R 3.5.2. The supporting CONSORT checklist and flowchart are available as supplemental information (Figure S1 CONSORT Checklist; Text S1 CONSORT Flowchart).

**Ethics statement**

The study protocols for the AHRI’s population-based HIV testing platform and HITS intervention were approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (BE290/16 and BFC398/16).34 Permission for the trial was obtained from the KwaZulu-Natal Department of Health, South Africa. Participation in the HIV surveillance and HITS trial is completely voluntary. Individuals may choose to opt out or refuse to answer any component of the HIV surveillance and to withdraw at any time. Written informed consent was sought from individuals aged ≥ 18 years, and parental or guardian consent with child assent for individuals of 15-17 years old were obtained.

**Results**

Overall, all 15,488 men living in the 45 clusters in the study area were initially considered eligible for inclusion in the first primary outcome of the trial – uptake of testing among men. Study participants were enrolled from February 2018 to December 2018. Of these, 1,650 died or out-migrated. Of the 13,838 remaining eligible men, 4,444 (32.1%) were never contacted (mainly due to absence at the time of HIV testing despite several attempts to follow up), 4,522 (32.7%) chose not to participate in the annual population-based HIV testing in 2018, and 453 (3.3%) reported being on ART, thus resulting in 4,419 (31.9% of the resident population) who participated in the population-based HIV testing (Figure 1). Randomization successfully achieved balance in respect of HIV prevalence and sociodemographic variables across the four arms except for the area of residency (Table 1). Those who participated in the population-based HIV testing were significantly younger, compared to those who were never contacted or chose not to participate (Table S1).

Among all 13,838 men ≥15 years living in the 45 communities in 2018, overall testing coverage was 27.4% (680/2481) in the financial incentives only arm, 17.0% (430/2534) in the EPIC-HIV only arm, 26.7% (566/2120) in the arm receiving both interventions, and 17.7% (1189/6703) in the SoC arm. In ITT analysis, compared to men in the SoC arm, the probability of HIV testing was 55% higher in the financial incentives only arm (risk ratio (RR)=1.55, 95% CI: 1.31-1.82, p<0.001) and 51% higher in the financial incentives plus EPIC-HIV arm receiving both interventions (RR=1.51, 95% CI: 1.21-1.87, p<0.001). The probability of HIV testing was not significantly different in the EPIC-HIV only arm (RR=0.96, 95% CI: 0.76-1.20, p=0.70) (Table 2; Figure 2).

When we examined HIV testing uptake by each of the interventions, the provision of financial incentives increased the uptake of home-based HIV testing by 55% (RR=1.55, 95% CI: 1.34-1.79). EPIC-HIV did not have any effect on the uptake of HIV testing at the time of testing offer (RR=1.05, 95% CI: 0.85-1.30, p=0.64). There was no interaction between financial incentives and EPIC-HIV (p-value=0.91).

When we limited the analysis to those who participated in the ongoing population-based HIV testing and thus were offered the interventions, 76.2% (680/893) in the financial incentives only arm, 75.8% (566/747) in the combined arm, 62.1% (430/692) in the EPIC-HIV only arm, and 57.0% (1189/2087) in the SoC arm consented and received the rapid HIV testing (Figure 1). Compared to men in the SoC arm, the probability of HIV testing was 34% higher in the financial incentives only arm (RR=1.34, 95% CI: 1.24-1.45, p<0.001) and 33% higher in the combined arm receiving both interventions (RR=1.33, 95% CI: 1.20-1.48, p<0.001). The probability of HIV testing was not significantly different in the EPIC-HIV only arm (RR=1.09, 95% CI: 0.98-1.21, p=0.10).

**Discussion**

In this study, we found that a small non-cash financial incentive (US$ 3) designed to provide an extrinsic motivation to test substantially increased the uptake of home-based HIV testing by more than 50% when offered either alone or in combination with a male-targeted HIV-specific decision support application. By contrast, the decision support application designed to act as an intrinsic motivator did not improve the uptake of home-based HIV testing at the time of testing offer. Our study is the first large trial to test the effects of extrinsic versus intrinsic motivators on uptake of home-based HIV testing specifically tailored and targeted to men.

A few studies have shown the positive effect of financial incentives on the uptake of HCT. In recent randomized controlled trials conducted in sub-Saharan Africa, financial incentives (i.e., both non-cash and cash incentives) significantly increased the uptake of HIV testing among men in Malawi19 or adolescents in Zimbabwe.20 On the other hand, most of previous cash transfer programmes among women and girls, which focused on changing sexual behaviours through creating positive social protection, found non-significant or marginal effects.37 Our results provide strong evidence that the relatively small once-off micro-incentives can play an important role in overcoming a barrier for accepting HIV testing at home environment among men.

There are several explanations as to why financial incentives were well accepted and significantly increased the uptake of HIV testing among men in this trial. We provided a fixed financial incentive which offered immediate, tangible, and easy-to-use benefit to everyone in the assigned intervention arms, rather than in some delayed manner or a chance of receiving it (i.e., lottery). In Malawi, while fixed incentives improved the uptake of HIV self-testing kits among men by up to 34%, the chance of winning a lottery for a larger amount did not result in any significant difference.19 Similarly, when either fixed incentives or a lottery were provided among adolescents in Zimbabwe, fixed incentives better increased HIV testing uptake than a lottery.20 We then offered home-based HIV testing which provided the convenient option once someone is nudged to accept testing.

We have not observed any effect of the male-sensitive HIV-specific decision support application (EPIC-HIV 1) on the uptake of home-based HIV testing. The application was developed to address the most important perceived barriers for the uptake of HCT such as psychosocial factors, or existing norms and encourage to take immediate action towards HCT. 38,39 However, unlike financial incentives which bring immediate and tangible benefit, overcoming psychosocial barriers through improving intrinsic motivation can be an iterative and slow process. Since HCT was offered right after the participants had listened to EPIC-HIV, they might have not yet been ready to make immediate action towards HCT. Nevertheless, in the post-intervention satisfaction surveys, 96% of participants who received EPIC-HIV 1 found EPIC-HIV 1 acceptable and motivated them to test, and almost everyone reported being empowered with the information from the app,40,41 suggesting that engagement with EPIC-HIV 1 would potentially lead to better uptake of home-based HIV testing or linkage to care in future.

The overall population coverage of HIV testing during this single round of testing was relatively low at 21% (with 32% of men away from home at the time of the fieldworker visits and 33% choosing not to participate in the annual population-based HIV testing), although over several rounds of testing, both the cumulative contact rate and the level of HIV testing would increase. For example, the consent rate to at least one HIV test reached over 75% between 2005 and 2016,31 and approximately half of the eligible individuals consented at least twice within five years of becoming eligible.42 Nevertheless, consistently reaching men for HIV testing and treatment remains a persistent challenge in this population and across multiple contexts.14,22,43 A recent systematic review showed that acceptability of home-based HIV testing greatly varies from 58.1% to 99.8% but with the high pooled proportion of 83.3% throughout sub-Saharan Africa.44 In the area neighbouring communities, where the ANRS TasP 12249 Trial was conducted, the uptake of home-based HIV testing was also high at 82.9%.12 When we limited our analysis to those who were present at home and offered the testing, the overall uptake of HIV testing was around 65%, and significantly higher in the intervention arms than in the SoC arm. Thus, it might require more than one visit to offer HIV testing and intervention in order to have a substantial impact at a population level.

Another challenge for delivering home-based HIV testing is frequent short-term mobility and long-term migration. In the study area, more than 20% of the residents migrate at least once in a given year, putting them at a higher risk of HIV acquisition and lack of access to HIV testing, prevention, or treatment services.45 Other innovative approaches have been shown effective to increase the uptake of HCT such as provision of HIV self-testing kits during delivery of home-based HIV testing services,46 at the community,47 or through female partners attending antenatal care clinics19 as well as finding men and offering tests at convenient locations (e.g. workplace) or via mobile testing.48,49 Financial incentives coupled with innovative approaches to reach men and offer HIV testing at different settings or improve access to self-testing kits may further improve the uptake of HIV testing.

The trial will further quantify the effect of financial micro-incentives and EPIC-HIV applications on enhancing linkage to care within 3 months to constitute the second primary outcome of the trial in late 2020. We will also quantify the long-term effects on HIV-related mortality among men and HIV incidence among young women by 2022.34 The trial has also collected detailed information on resources used to implement and deliver the interventions using micro-costing and a time-and-motion approach and will quantify the cost-effectiveness of financial micro-incentives and EPIC-HIV application to improve HIV testing uptake and linkage to care. A study in Tanzania showed that willingness-to-accept estimates for financially incentivized universal HIV testing among adults were $1.3-$6.4 and considered highly cost-effective,50 but there is very limited evidence for cost-effectiveness of both financial incentives and behavioural intervention in general population using the data from randomized clinical trials. Our study findings will provide important insights into the efficacy, cost-effectiveness, and sustainability of once-off micro-incentives and decision support application to reach men and improve long-term population health outcomes in hyperendemic HIV settings.

The study has several important strengths. The study was the first of its kind and was delivered as a community-randomized clinical trial among over 13,800 men in 45 communities nested within one of the world’s largest ongoing population-based HIV cohorts. This allowed the unbiased measuring the effect of the interventions where home-based HIV testing at households was a standard of care, controlling for potential contextual factors and differences across the communities, and provided sufficient power to detect the effects of interventions. In some randomized clinical trials, treatment non-adherence or crossover among randomized groups may cause treatment contamination, thus a statistical approach like instrumental variables would be beneficial to adjust for treatment contamination.51 In our study, however, every participant was offered and received interventions as randomized (i.e., no contamination of randomized interventions), further validating our intention-to-treat analysis. However, the study is not without limitations. In particular, men who did not participate in the annual HIV testing survey were not eligible to receive interventions in the study, thus ultimately limiting the potential population coverage of the interventions.

**Conclusions**

In summary, we found that a small, once-off, financial incentive significantly improved the uptake of home-based HIV testing by more than 50% among men in this large community-randomized clinical trial. By contrast, the counselling and testing application which was designed to serve as an intrinsic motivator for HIV testing did not increase the uptake of home-based testing. Financial micro-incentives could be considered as an effective strategy to encourage the uptake of home-based HIV testing, especially among the unreached population with a lower uptake of HCT.

**Competing interests**

All co-authors declare no conflict of interest.

**Authors’ contributions**

FT and TB are the principal investigators and developed the study design and protocol in collaboration with MS, SW, NM, JS, HMY, BS, and AD. H-YK & FT analysed the data and wrote the first draft of the manuscript. PM, AB, AZ, OA, TM, TZ, SW, JS, and MS were involved in the development of EPIC-HIV. All authors read and approved the final manuscript.

**Acknowledgements**

The authors wish to thank the colleagues at AHRI supporting day-to-day project operations and all study participants.

Funding:The research is funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Number R01AI124389 (PIs: Frank Tanser and Till Bärnighausen). EPIC-HIV development was supported by the Engineering and Physical Sciences Research Council (EPSRC) Interdisciplinary Research Collaboration (IRC) Early-warning Sensing Systems for Infectious Diseases (i-sense) EP/K031953/1 and MRC MR/P024378/1. Frank Tanser and Till Bärnighausen are also supported by NIH grant (R01-HD084233). The Africa Health Research Institute’s Demographic Surveillance Information System and Population Intervention Programme is funded by the Wellcome Trust (201433/Z/16/Z), and the South Africa Population Research Infrastructure Network (funded by the South African Department of Science and Technology and hosted by the South African Medical Research Council). N. McGrath is a recipient of an NIHR Research Professorship award (Ref: RP-2017-08-ST2-008). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding bodies.

**List of abbreviations**

Abbreviation: AHRI, Africa Health Research Institute; CONSORT, Consolidated Standards of Reporting Trials; EPIC-HIV, Empowering People through Informed Choices for HIV; HCT, HIV Counseling and Testing; HIV, Human Immunodeficiency Virus; HITS, Home-Based Intervention to Test and Start.

**Table 1. Characteristics of communities and eligible male participants by intervention arms in KwaZulu-Natal, South Africa, 2018**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Characteristic | **Financial incentives only** | **Financial incentives plus EPIC-HIV** | **EPIC-HIV only** | **Standard of care** |
| HIV prevalence in 2018, % (95% CI)\* | 18.5  (15.9-21.3) | 15.0  (12.4-17.9) | 19.3  (16.2-22.7) | 17.6  (15.9-19.5) |
| Time since last HIV test in the surveillance (years), median (IQR)\*\* | 2.5 (0.6, 6.0) | 2.3 (1.0, 5.3) | 2.3 (1.0, 5.6) | 2.3 (1.0, 5.5) |
| ***Individual-level factors*** | **n= 2481** | **n=2120** | **n=2534** | **n=6703** |
| **Age (years), % (n)** |  |  |  |  |
| 15-25 | 36.5 (906) | 37.6 (796) | 35.6 (902) | 37.2 (2492) |
| 25-35 | 22.5 (558) | 23.4 (495) | 22.3 (566) | 23.4 (1566) |
| 35-45 | 16.5 (410) | 13.9 (295) | 15.8 (400) | 15.7 (1051) |
| 45-55 | 10.4 (258) | 10.2 (217) | 10.1 (257) | 9.7 (647) |
| ≥55 | 14.1 (349) | 14.9 (315) | 16.1 (409) | 14.1 (946) |
| **Marital Status, % (n)** |  |  |  |  |
| Never married | 26.9 (668) | 25.9 (550) | 26.2 (664) | 26.8 (1798) |
| Married | 14.2 (352) | 14.6 (309) | 15.6 (396) | 14.2 (951) |
| Informal Union | 40.1 (995) | 38.3 (811) | 37.9 (960) | 38.5 (2584) |
| Separated/Divorced/Widowed | 1.4 (35) | 2.1 (45) | 2.1 (52) | 1.9 (125) |
| Don't know/Missing | 17.4 (431) | 19.1 (405) | 18.2 (462) | 18.6 (1245) |
| **Education, % (n)** |  |  |  |  |
| No formal education | 23.9 (594) | 26.0 (552) | 25.3 (640) | 24.8 (1665) |
| Primary (grade 1-7) | 6.3 (156) | 6.5 (138) | 6.8 (172) | 6.4 (432) |
| Secondary+ (≥ grade 8) | 69.8 (1731) | 67.5 (1430) | 68.0 (1722) | 68.7 (4606) |
| **Area of residency, % (n)** |  |  |  |  |
| Rural | 59.9 (1485) | 52.7 (1117) | 60.5 (1532) | 58.3 (3905) |
| Peri-urban | 32.8 (813) | 47.3 (1003) | 26.5 (671) | 33.9 (2275) |
| Urban | 7.4 (183) | 0.0 (0) | 13.1 (331) | 7.8 (523) |

\*95% confidence intervals were calculated using the cumulative probabilities of the binomial distribution.

Abbreviation: EPIC, Empowering People through Informed Choices for HIV; IQR, interquartile range


**Table 2. Consenting and uptake of HIV testing among all 13,838 eligible men by intervention arms**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Total number of eligible participants | Consented for interventions | Received rapid HIV testing | Risk Ratios  (95% CI) |
|  | N=13,838 | N=1,759 | N=2,865 |  |
| **Intervention group analysis** |  | No. (%) | No. (%) |  |
| Financial incentives only | 2481 | 686 (27.7) | 680 (27.4) | 1.55 (1.31-1.82) |
| Financial incentives plus EPIC-HIV | 2120 | 605 (28.5) | 566 (26.7) | 1.51 (1.21-1.87) |
| EPIC-HIV only | 2534 | 468 (18.5) | 430 (17.0) | 0.96 (0.76-1.20) |
| Standard of care | 6703 | n/a | 1189 (17.7) | Reference |
|  |  |  |  |  |
| **Factorial analysis** |  |  |  |  |
| Financial incentives | 4601 | 1252 (27.2) | 1246 (27.1) | 1.55 (1.34-1.79) |
| No financial incentives | 9237 | n/a | 1619 (17.5) | Reference |
|  |  |  |  |  |
| **Factorial analysis** |  |  |  |  |
| EPIC-HIV | 4654 | 1037 (22.3) | 996 (21.4) | 1.05 (0.85-1.30) |
| No EPIC-HIV | 9184 | n/a | 1869 (20.4) | Reference |

Abbreviation: EPIC, Empowering People through Informed Choices for HIV



**Figure 1. Flow diagram for HITS trial.** Flow diagram shows individual flow through each stage of the cluster randomized controlled trial by intervention arms. Abbreviation: EPIC, Empowering People through Informed Choices for HIV.



Risk Ratio with 95% Confidence Interval

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **HIV testing uptake** | **Financial incentives only** | **Financial incentives plus EPIC-HIV** | **EPIC-HIVonly** | **Standard of care** |
| Number | 680/2481 | 430/2534 | 566/2120 | 1189/6703 |
| Percentage | 27.4% | 26.7% | 17.0% | 17.7% |
| Risk ratio of HIV testing uptake (95% CI) | 1.55 (1.31, 1.82) | 1.51 (1.21, 1.87) | 0.96 (0.76, 1.20) | Reference |

**Figure 2.** Risk ratio (RR) of HIV testing uptake in the full intent to treat analysis among all eligible men. The circle symbol with the error bar represents the RR with 95% confidence interval in each arm compared to the standard of care arm. Percentage (%) indicates the percentage of HIV testing uptake.

**References**

1 Bor J, Herbst AJ, Newell M-L, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. *Science* 2013; **339**: 961–5.

2 Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. *Science* 2013; **339**: 966–71.

3 Tanser F, Bärnighausen T, Dobra A, Sartorius B. Identifying ‘corridors of HIV transmission’ in a severely affected rural South African population: A case for a shift toward targeted prevention strategies. *Int J Epidemiol* 2018; **47**: 537–49.

4 Chimbindi N, Mthiyane N, Birdthistle I, *et al.* Persistently high incidence of HIV and poor service uptake in adolescent girls and young women in rural KwaZulu-Natal, South Africa prior to DREAMS. *PLoS One* 2018; **13**: e0203193.

5 Birdthistle I, Tanton C, Tomita A, *et al.* Recent levels and trends in HIV incidence rates among adolescent girls and young women in high-prevalence countries: A systematic review and meta-analysis. *Lancet Glob Heal* 2019; **7**: E1521-1540.

6 Bor J, Rosen S, Chimbindi N, *et al.* Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa. *PLOS Med* 2015; **12**: e1001905.

7 Hensen B, Lewis JJ, Schaap A, *et al.* Factors Associated with HIV-Testing and Acceptance of an Offer of Home-Based Testing by Men in Rural Zambia. *AIDS Behav* 2015; **19**: 492–504.

8 Vandormael A, Akullian A, Siedner M, Bärnighausen T, de Oliveira T, Tanser F. Declines in HIV incidence among men and women in a South African population-based cohort. *Nat Commun* 2019; **10**: 5482.

9 Havlir D V., Balzer LB, Charlebois ED, *et al.* HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. *N Engl J Med* 2019; **381**: 219–29.

10 Makhema J, Wirth KE, Pretorius Holme M, *et al.* Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. *N Engl J Med* 2019; **381**: 230–42.

11 Hayes RJ, Donnell D, Floyd S, *et al.* Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART). *N Engl J Med* 2019; **381**: 207–18.

12 Iwuji CC, Orne-Gliemann J, Larmarange J, *et al.* Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. *Lancet HIV* 2018; **5**: e116–25.

13 Galárraga O, Genberg BL, Martin RA, Barton Laws M, Wilson IB. Conditional Economic Incentives to Improve HIV Treatment Adherence: Literature Review and Theoretical Considerations. *AIDS Behav* 2013; **17**: 2283–92.

14 Metsch LR, Feaster DJ, Gooden L, *et al.* Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial. *JAMA* 2016; **316**: 156–70.

15 Thirumurthy H, Masters SH, Rao S, *et al.* Effect of providing conditional economic compensation on uptake of voluntary medical male circumcision in Kenya: a randomized clinical trial. *JAMA* 2014; **312**: 703–11.

16 Gaarder MM, Glassman A, Todd JE. Conditional cash transfers and health: unpacking the causal chain. *J Dev Eff* 2010; **2**: 6–50.

17 Lagarde M, Haines A, Palmer N. Conditional cash transfers for improving uptake of health interventions in low- and middle-income countries: A systematic review. JAMA. 2007; **298**: 1900–10.

18 Bassett I V, Wilson D, Taaffe J, Freedberg KA. Financial incentives to improve progression through the HIV treatment cascade. *Curr Opin HIV AIDS* 2015; **10**: 451–63.

19 Choko AT, Corbett EL, Stallard N, *et al.* HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial. *PLoS Med* 2019; **16**: e1002719.

20 Kranzer K, Simms V, Bandason T, *et al.* Economic incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial. *lancet HIV* 2018; **5**: e79–86.

21 McNairy ML, Lamb MR, Gachuhi AB, *et al.* Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial. *PLoS Med* 2017; **14**.

22 Elul B, Lamb MR, Lahuerta M, *et al.* A combination intervention strategy to improve linkage to and retention in HIV care following diagnosis in Mozambique: A cluster-randomized study. *PLOS Med* 2017; **14**: e1002433.

23 El-Sadr WM, Donnell D, Beauchamp G, *et al.* Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients. *JAMA Intern Med* 2017; **177**: 1083.

24 Adamson B, El-Sadr W, Dimitrov D, *et al.* The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. *Value Heal* 2019; **22**: 194–202.

25 Maughan-Brown B, Smith P, Kuo C, *et al.* A Conditional Economic Incentive Fails to Improve Linkage to Care and Antiretroviral Therapy Initiation Among HIV-Positive Adults in Cape Town, South Africa. *AIDS Patient Care STDS* 2018; **32**: 70–8.

26 Galarraga O, Sosa-Rubi SG, Kuo C, *et al.* Punto Seguro: A Randomized Controlled Pilot Using Conditional Economic Incentives to Reduce Sexually Transmitted Infection Risks in Mexico. *AIDS Behav* 2017; **21**: 3440–56.

27 Camlin CS, Ssemmondo E, Chamie G, *et al.* Men &quot;missing&quot; from population-based HIV testing: insights from qualitative research. *AIDS Care* 2016; **28 Suppl 3**: 67–73.

28 Rhead R, Skovdal M, Takaruza A, Maswera R, Nyamukapa C, Gregson S. The multidimensionality of masculine norms in east Zimbabwe. *AIDS* 2019; **33**: 537–46.

29 Baisley KJ, Seeley J, Siedner MJ, *et al.* Findings from home-based HIV testing and facilitated linkage after scale-up of test and treat in rural South Africa: young people still missing. *HIV Med* 2019; **20**: 704–8.

30 Tanser F, Hosegood V, Bärnighausen T, *et al.* Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. *Int J Epidemiol* 2008; **37**: 956–62.

31 Vandormael A, De Oliveira T, Tanser F, Bärnighausen T, Herbeck JT. High percentage of undiagnosed HIV cases within a hyperendemic South African community: A population-based study. *J Epidemiol Community Health* 2018; **72**: 168–72.

32 Muhwava W, Nyirenda M, Mutevedzi T, Herbst A, Hosegood V. Operational and Methodological Procedures of the Africa Centre Demographic Information System. 2007.

33 Osler M, Hilderbrand K, Hennessey C, *et al.* A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. *J Int AIDS Soc* 2014; **17**: 18908.

34 Mathenjwa T, Kim H-Y, Zuma T, *et al.* Home-based intervention to test and start (HITS) protocol: a cluster-randomized controlled trial to reduce HIV-related mortality in men and HIV incidence in women through increased coverage of HIV treatment. *BMC Public Health* 2019; **19**: 969.

35 Tanser FC. The application of GIS technology to equitably distribute fieldworker workload in a large, rural South African health survey. *Trop Med Int Heal* 2002; **7**: 80–90.

36 Yardley L, Morrison L, Bradbury K, Muller I. The Person-Based Approach to Intervention Development: Application to Digital Health-Related Behavior Change Interventions. *J Med Internet Res* 2015; **17**: e30.

37 Pettifor A, MacPhail C, Hughes JP, *et al.* The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial. *Lancet Glob Heal* 2016; **4**: e978–88.

38 Armstrong-Hough M, Ggita J, Ayakaka I, *et al.* ‘Give me some time’: Facilitators of and barriers to uptake of home-based HIV testing during household contact investigation for tuberculosis in Kampala, Uganda. *J Acquir Immune Defic Syndr* 2018; **77**: 400–4.

39 Berendes S, Rimal RN. Addressing the Slow Uptake of HIV Testing in Malawi: The Role of Stigma, Self-efficacy, and Knowledge in the Malawi BRIDGE Project. *J Assoc Nurses AIDS Care* 2011; **22**: 215–28.

40 Adeagbo O, Tanser F, Gumede V, *et al.* A Process Evaluation of an Incentivised Home-based Intervention to Test and Start (HITS) in an HIV Hyperendemic setting in rural KwaZulu-Natal, South Africa. *Sex Transm Infect* 2019; **95**.

41 Adeagbo O, Kim H-Y, Tanser F, *et al.* Acceptability of a tablet-based application to support early HIV testing among men in rural KwaZulu-Natal, South Africa: a mixed method study. *AIDS Care* 2020; **March 15**: 1–8.

42 Larmarange J, Mossong J, Bärnighausen T, Newell ML. Participation dynamics in population-based longitudinal HIV surveillance in rural South Africa. *PLoS One* 2015; **10**: 1–16.

43 Thirumurthy H, Ndyabakira A, Marson K, *et al.* Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial. *Lancet HIV* 2019; **6**: e155–63.

44 Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of Home-Based Voluntary HIV Testing in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. *PLoS Med* 2012; **9**: e1001351.

45 Dobra A, Bärnighausen T, Vandormael A, Tanser F. Space-time migration patterns and risk of HIV acquisition in rural South Africa. *AIDS* 2017; **31**: 137–45.

46 Mulubwa C, Hensen B, Phiri MM, *et al.* Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities. *Lancet HIV* 2019; **6**: e81–92.

47 Shapiro AE, Heerden A, Krows M, *et al.* An implementation study of oral and blood‐based HIV self‐testing and linkage to care among men in rural and peri‐urban KwaZulu‐Natal, South Africa. *J Int AIDS Soc* 2020; **23**. DOI:10.1002/jia2.25514.

48 Corbett EL, Dauya E, Matambo R, *et al.* Uptake of workplace HIV counselling and testing: A cluster-randomised trial in Zimbabwe. *PLoS Med* 2006; **3**: 1005–12.

49 Van Rooyen H, McGrath N, Chirowodza A, *et al.* Mobile VCT: Reaching men and young people in urban and rural South African pilot studies (NIMH Project Accept, HPTN 043). *AIDS Behav* 2013; **17**: 2946–53.

50 Ostermann J, Brown DS, Mühlbacher A, Njau B, Thielman N. Would you test for 5000 Shillings? HIV risk and willingness to accept HIV testing in Tanzania. *Health Econ Rev* 2015; **5**. DOI:10.1186/s13561-015-0060-8.

51 Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. *BMJ* 2010; **340**: 1181–4.